Mainz Biomed N.V. Appoints Robert P. Liscouski As Chairman and Announces Name Change To Quantum Cyber With New Nasdaq Ticker Launching March 12, 2026

Mainz Biomed N.V., a molecular genetics diagnostics company focused on early cancer detection, announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Alongside this leadership update, the company revealed plans to change its name to Quantum Cyber and transition its Nasdaq ticker symbol to QUCY starting March 12, 2026. These changes, along with the formal election of Mr. Liscouski, will be finalized at an extraordinary general meeting scheduled for April 2026. The business will begin operating under the Quantum Cyber name and trading as QUCY on March 12, ahead of the shareholder vote.

Mr. Liscouski is widely recognized for his expertise in national security and cybersecurity, and he has frequently appeared on major media outlets including CNBC, CNN, BBC, and Fox News to discuss homeland security and terrorism-related issues. He has also provided testimony before Congress on matters of national security. He holds a Master of Public Administration from the John F. Kennedy School of Government at Harvard University.

Earlier in his career, Mr. Liscouski was appointed by President George W. Bush as the first Assistant Secretary for Infrastructure Protection at the newly formed U.S. Department of Homeland Security in 2003. In that role, he oversaw the development, implementation, and long-term management of the Office of Infrastructure Protection. His work involved integrating units from agencies including the FBI, the Department of Defense, the General Services Administration, the Department of Energy, and the Department of Commerce. His efforts were foundational in the eventual establishment of today’s Critical Infrastructure and Security Agency, commonly known as CISA.

In the private sector, Mr. Liscouski has been a prominent figure in cybersecurity, quantum computing, and advanced AI-driven technologies. He most recently served as co-founder, CEO, and Chairman of Quantum Computing Inc., a company focused on integrated photonics and accessible quantum hardware. He has also co-founded Fog Data Sciences, LLC, where he helped develop AI-driven geolocation intelligence solutions for law enforcement and national security agencies. 

Earlier in his career, he served as Director of Information Assurance at The Coca-Cola Company, leading the evaluation and development of the company’s global information security program. Mainz Biomed previously outlined its intention to prioritize its pancreatic cancer screening program in the United States and explore opportunities to divest its colorectal cancer screening assets. The company also continues the process of winding down its German subsidiary as part of its strategic refocusing.

David Lazar, the outgoing Chairman of the Board, welcomed Mr. Liscouski’s appointment, noting his extensive experience across technology, cybersecurity, and critical infrastructure. He emphasized Mr. Liscouski’s leadership in pioneering quantum computing technologies particularly through his work at Quantum Computing Inc. aligns well with the company’s long-term ambitions as it transitions into Quantum Cyber. Lazar added that Mr. Liscouski’s background spanning both government and industry positions him strongly to guide the company through its next phase of development.